https://orcid.org/0000-0001-8832-2562
References
- Colomban O, Tod M, Leary A, et al. Early modeled longitudinal CA-125 kinetics and survival of ovarian cancer patients: a GINECO AGO MRC CTU study. Clin Cancer Res Off J Am Assoc Cancer Res. 2019;25(17):5342–5350. doi:10.1158/1078-0432.CCR-18-3335
- Lauby A, Colomban O, Corbaux P, et al. The increasing prognostic and predictive roles of the tumor primary chemosensitivity assessed by CA-125 Elimination Rate Constant K (KELIM) in ovarian cancer: a narrative review. Cancers (Basel). 2021;14(1):98. doi:10.3390/cancers14010098
- Corbaux P, You B, Glasspool RM, et al. Survival and modelled cancer antigen-125 ELIMination rate constant K score in ovarian cancer patients in first-line before poly(ADP-ribose) polymerase inhibitor era: a Gynaecologic Cancer Intergroup meta-analysis. Eur J Cancer Oxf Engl 1990. 2023;191:112966. doi:10.1016/j.ejca.2023.112966
- You B, Van Wagensveld L, Tod M, et al. Low probability of disease cure in advanced ovarian carcinomas before the PARP inhibitor era. Br J Cancer 2022;127(1):79–83. doi:10.1038/s41416-022-01732-7